Since 2011 the landscape of melanoma has changed with new treatments, including targeted therapies such as BRAF inhibitors (dabrafenib and vemurafenib), and MEK inhibitors—(trametinib and cobimetinib), as well as immunotherapies including anti‐CTLA‐4 antibody (ipilimumab), and anti‐PD‐1 antibodies (pembrolizumab and nivolumab). The gene discussed is BRAF; the disease is melanoma.